Lipocine (LPCN) Cash & Equivalents Growth (1y) (2012 - 2025)
Lipocine (LPCN) Cash & Equivalents Growth (1y) (2012 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 23.56% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.05% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 71.81% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 34.71% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 84.98% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 53.39% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -14.35% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -57.58% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 28.50% |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | -34.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -34.28% |
| Sep 30, 2025 | -24.01% |
| Jun 30, 2025 | -22.41% |
| Mar 31, 2025 | -19.54% |
| Dec 31, 2024 | -1.72% |
| Sep 30, 2024 | -17.31% |
| Jun 30, 2024 | -11.41% |
| Mar 31, 2024 | -13.91% |
| Dec 31, 2023 | -31.54% |
| Sep 30, 2023 | -28.91% |
| Jun 30, 2023 | -30.93% |
| Mar 31, 2023 | -30.94% |
| Dec 31, 2022 | -29.93% |
| Sep 30, 2022 | -11.78% |
| Jun 30, 2022 | -18.94% |
| Mar 31, 2022 | 164.07% |
| Dec 31, 2021 | 138.22% |
| Sep 30, 2021 | 195.45% |
| Jun 30, 2021 | 231.35% |
| Mar 31, 2021 | 3.08% |